Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Farmers Insurance
Cantor Fitzgerald
US Army
Argus Health
Citi
Chinese Patent Office
Fuji
Teva
Merck

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,399,496

« Back to Dashboard

Which drugs does patent 8,399,496 protect, and when does it expire?

Patent 8,399,496 protects CAYSTON and is included in one NDA.

This patent has thirty-nine patent family members in eighteen countries.
Summary for Patent: 8,399,496
Title:Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
Inventor(s): Montgomery; Alan Bruce (Seattle, WA), Keller; Manfred (Munchen, DE), Lintz; Frank-Christophe (Starnberg, DE)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/229,425
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation;

Drugs Protected by US Patent 8,399,496

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,399,496

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,660,249 Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections ➤ Try a Free Trial
7,214,364 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Try a Free Trial
7,427,633 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Try a Free Trial
9,345,663 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Try a Free Trial
9,533,000 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections ➤ Try a Free Trial
8,841,286 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Try a Free Trial
7,138,419 Process for manufacturing bulk solutions and a lyophilized pure .alpha.-aztreonam lysinate ➤ Try a Free Trial
7,208,141 Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,399,496

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 053305 ➤ Try a Free Trial
Austria 502623 ➤ Try a Free Trial
Australia 2002231244 ➤ Try a Free Trial
Australia 2004257632 ➤ Try a Free Trial
Australia 2009233632 ➤ Try a Free Trial
Australia 2012202089 ➤ Try a Free Trial
Australia 2014271333 ➤ Try a Free Trial
Australia 2017200384 ➤ Try a Free Trial
Brazil 0116757 ➤ Try a Free Trial
Brazil PI0411949 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Moodys
Cipla
Cerilliant
Healthtrust
Accenture
Mallinckrodt
Medtronic
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot